Douglas S Krafte

Summary

Affiliation: Icagen Inc
Country: USA

Publications

  1. ncbi request reprint Block of Nav1.8 by small molecules
    Douglas S Krafte
    Icagen, Inc, Durham, North Carolina 14487, USA
    Channels (Austin) 1:152-3. 2007
  2. ncbi request reprint Sodium channels and nociception: recent concepts and therapeutic opportunities
    Douglas S Krafte
    Icagen Inc, P O Box 14487, Research Triangle Park, NC 27709, USA
    Curr Opin Pharmacol 8:50-6. 2008
  3. ncbi request reprint Tenidap, a novel anti-inflammatory agent, is an opener of the inwardly rectifying K+ channel hKir2.3
    Yi Liu
    Icagen, Inc, 4222 Emperor Boulevard, Suite 460, Durham, NC 27703, USA
    Eur J Pharmacol 435:153-60. 2002
  4. ncbi request reprint Decrease of inward rectification as a mechanism for arachidonic acid-induced potentiation of hKir2.3
    Yi Liu
    Icagen, Inc, 4222 Emperor Boulevard, Suite 460, Durham, NC 27703, USA
    Eur Biophys J 31:497-503. 2002
  5. doi request reprint The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons
    Xin Su
    Icagen, Inc, Durham, North Carolina, USA
    Anesth Analg 109:632-40. 2009
  6. pmc Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels
    Ken McCormack
    Icagen Inc currently Neusentis, Research Unit of Pfizer Inc, Durham, NC 27703, USA
    Proc Natl Acad Sci U S A 110:E2724-32. 2013
  7. doi request reprint Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain
    Irene Drizin
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem 16:6379-86. 2008
  8. pmc A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat
    Michael F Jarvis
    Neuroscience Research, Abbott Laboratories, Abbott Park, IL 60064, USA
    Proc Natl Acad Sci U S A 104:8520-5. 2007
  9. doi request reprint Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain
    Michael E Kort
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6100, USA
    J Med Chem 51:407-16. 2008
  10. ncbi request reprint An interview with Douglas S. Krafte, Ph.D. Interview by Vicki P. Glaser
    Douglas S Krafte
    Assay Drug Dev Technol 4:1-5. 2006

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Block of Nav1.8 by small molecules
    Douglas S Krafte
    Icagen, Inc, Durham, North Carolina 14487, USA
    Channels (Austin) 1:152-3. 2007
    ....
  2. ncbi request reprint Sodium channels and nociception: recent concepts and therapeutic opportunities
    Douglas S Krafte
    Icagen Inc, P O Box 14487, Research Triangle Park, NC 27709, USA
    Curr Opin Pharmacol 8:50-6. 2008
    ..All of these data are converging to suggest next generation sodium channel blockers may offer the potential for novel pain therapies in the future...
  3. ncbi request reprint Tenidap, a novel anti-inflammatory agent, is an opener of the inwardly rectifying K+ channel hKir2.3
    Yi Liu
    Icagen, Inc, 4222 Emperor Boulevard, Suite 460, Durham, NC 27703, USA
    Eur J Pharmacol 435:153-60. 2002
    ..1, Kv1.5, and micro1 Na+ channels. Our results demonstrate that tenidap is a potent opener of hKir2.3 and suggest that it can serve as a valuable pharmacological tool for studying physiological and pathological processes involving Kir2.3...
  4. ncbi request reprint Decrease of inward rectification as a mechanism for arachidonic acid-induced potentiation of hKir2.3
    Yi Liu
    Icagen, Inc, 4222 Emperor Boulevard, Suite 460, Durham, NC 27703, USA
    Eur Biophys J 31:497-503. 2002
    ..These results are consistent with the idea that AA potentiates hKir2.3 in part by decreasing inward rectification of the channel...
  5. doi request reprint The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons
    Xin Su
    Icagen, Inc, Durham, North Carolina, USA
    Anesth Analg 109:632-40. 2009
    ..In this study, we examined structurally diverse kappa-ORAs for their abilities to inhibit tetrodotoxin-resistant (TTX-r) sodium channels in adult rat DRGs...
  6. pmc Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels
    Ken McCormack
    Icagen Inc currently Neusentis, Research Unit of Pfizer Inc, Durham, NC 27703, USA
    Proc Natl Acad Sci U S A 110:E2724-32. 2013
    ..The present study provides a potential framework for identifying subtype selective small molecule sodium channel inhibitors targeting interaction sites away from the pore region. ..
  7. doi request reprint Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain
    Irene Drizin
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem 16:6379-86. 2008
    ....
  8. pmc A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat
    Michael F Jarvis
    Neuroscience Research, Abbott Laboratories, Abbott Park, IL 60064, USA
    Proc Natl Acad Sci U S A 104:8520-5. 2007
    ..These data demonstrate that acute and selective pharmacological blockade of Na(v)1.8 sodium channels in vivo produces significant antinociception in animal models of neuropathic and inflammatory pain...
  9. doi request reprint Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain
    Michael E Kort
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6100, USA
    J Med Chem 51:407-16. 2008
    ..2, Nav1.5, Nav1.7) and human ether-a-go-go (hERG) channels. Following systemic administration, compounds 7 and 27 dose-dependently reduced neuropathic and inflammatory pain in experimental rodent models...
  10. ncbi request reprint An interview with Douglas S. Krafte, Ph.D. Interview by Vicki P. Glaser
    Douglas S Krafte
    Assay Drug Dev Technol 4:1-5. 2006